Table 2.
Outcomes in PKG+ and PG− arms.
| 1st visit Mean (SD) |
Last visit Mean (SD) |
||||
|---|---|---|---|---|---|
| P value | Δ (SEM) | 95% CI | |||
| PKG+ (N = 75) | |||||
| UPDRSa Total | 59.6 ± 16.9 | 51.1 ± 14.7 | 0.001* | 8.5 ± 2.6 | 3.4–14 |
| UPDRS IV | 5.0 ± 3.8 | 3.5 ± 3.0 | 0.01* | 1.5 ± 0.6 | 0.4–2.6 |
| UPDRS III | 35.1 ± 9.6 | 28.6 ± 7.9 | <0.001* | 6.4 ± 1.4 | 3.6–9.2 |
| UPDRS II | 9.5 ± 5.8 | 9.2 ± 5.5 | 0.74 | 0.3 ± 0.9 | −1.5 to 2.1 |
| UPDRS I | 10.5 ± 4.9 | 9.9 ± 4.9 | 0.41 | 0.7 ± 0.8 | −0.9 to 2.2 |
| PDQ39b | 26.9 ± 16.8 | 22.2 ± 13.5 | 0.07 | 4.7 ± 2.5 | −0.2 to 9.5 |
| SENS PDc | 11.1 ± 4.9 | 9.9 ± 4.6 | 0.13 | 1.2 ± 0.8 | −0.3 to 2.7 |
| NMSQd | 8.8 ± 5.2 | 8.4 ± 5.3 | 0.70 | 0.3 ± 0.9 | −1.3 to 2.0 |
| LEDDe | 675 ± 330 | 799 ± 380 | 0.04* | −124 ± 58 | −237 to −9.5 |
| MoCAf | 26.5 ± 2.1 | 26.8 ± 2.3 | 0.42 | −0.3 ± 0.4 | −1.0 to 0.4 |
| mBKSg | 25.2 ± 5.5 | 23.8 ± 3.8 | 0.08 | 1.4 ± 0.8 | −0.1 to 2.9 |
| AmBKSh | 22.6 ± 5.3 | 21.1 ± 3.9 | 0.046 | 1.5 ± 0.8 | 0.0 to 3.0 |
| PTOTi | 19.9 ± 17.5 | 13.0 ± 11.0 | 0.005* | 6.9 ± 2.4 | 2.2 to 12 |
| PTTj | 4.9 ± 8.8 | 2.9 ± 5.2 | 0.10 | 2.0 ± 1.2 | −0.3 to 4.3 |
| PTIk | 6.2 ± 5.3 | 5.5 ± 4.9 | 0.36 | 0.8 ± 0.8 | −0.9 to 2.4 |
| mDKSl | 3.3 ± 3.7 | 3.2 ± 2.7 | 0.79 | 0.1 ± 0.5 | −0.9 to 1.2 |
| PTDm | 11.5 ± 10.8 | 12.8 ± 9.5 | 0.44 | −1.3 ± 1.7 | −4.6 to 1.9 |
| PKG− (N = 79) | |||||
| UPDRS Total | 62.3 ± 19.8 | 57.4 ± 17.6 | 0.10 | 4.9 ± 3.0 | −1.0 to 10.7 |
| UPDRS IV | 4.6 ± 3.7 | 4.0 ± 3.4 | 0.24 | 0.7 ± 0.6 | −0.4 to 1.8 |
| UPDRS III | 35.8 ± 11.4 | 33.2 ± 10.1 | 0.13 | 2.6 ± 1.7 | −0.7 to 6.0 |
| UPDRS II | 10.7 ± 6.6 | 9.8 ± 6.2 | 0.39 | 0.9 ± 1.0 | −1.1 to 2.9 |
| UPDRS I | 11.2 ± 6.1 | 10.6 ± 4.9 | 0.52 | 0.6 ± 0.9 | −1.2 to 2.3 |
| PDQ39 | 29.6 ± 19.2 | 25.6 ± 18.4 | 0.19 | 4.0 ± 3.0 | −1.9 to 9.9 |
| SENS PD | 12.1 ± 5.3 | 11.4 ± 5.0 | 0.45 | 0.60.8 | −1.0 to 2.2 |
| NMSQ | 9.7 ± 4.9 | 8.8 ± 4.7 | 0.26 | 0.9 ± 0.8 | −0.6 to 2.4 |
| LEDD | 760 ± 327 | 870 ± 376 | 0.06 | −110 ± 56 | −220 to 0.9 |
| MoCA | 25.9 ± 2.5 | 26.6 ± 2.8 | 0.14 | −0.6 ± 0.4 | −1.5 to 0.2 |
| mBKS | 26.4 ± 5.8 | 25.4 ± 5.6 | 0.24 | 1.1 ± 0.9 | −0.7 to 2.9 |
| AmBKS | 23.9 ± 5.6 | 23.1 ± 5.6 | 0.35 | 0.8 ± 0.9 | −0.9 to −2.6 |
| PTOT | 24.6 ± 20.9 | 20.3 ± 18.3 | 0.18 | 4.2 ± 3.1 | −1.9 to 10.4 |
| PTT | 5.8 ± 8.1 | 4.5 ± 6.9 | 0.31 | 1.2 ± 1.2 | −1.1 to 3.6 |
| PTI | 6.5 ± 6.4 | 6.6 ± 6.1 | 0.96 | 0.0 ± 1.0 | −2.0 to 1.9 |
| mDKS | 3.1 ± 4.5 | 3.2 ± 3.6 | 0.87 | −0.1 ± 0.7 | −1.4 to 1.2 |
| PTD | 10.4 ± 12.3 | 12.7 ± 11.6 | 0.24 | −2.3 ± 1.9 | −6.0 to 1.5 |
*P < 0.05.
aMovement Disorder Society Unified Parkinson’s Disease Rating Scale. bParkinson’s Disease Quality of Life 39 Questions. cSeverity of predominantly Non-dopaminergic Symptoms in Parkinson’s Disease. dNon-Motor Symptoms Questionnaire. eLevodopa Equivalent Daily Dose. fMontreal Cognitive Assessment. gMedian of 2 min Bradykinesia Scores. hMedian of 2 min Active Bradykinesia Scores; iPercent time over target. jPercent time in tremor. kPercent time immobile (day time sleep surrogate): mDKS. lMedian of 2 min Dyskinesia Scores: PTD. mPercent time in dyskinesia.